Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization

European Journal of Ophthalmology

Volumn 17, Issue 4, 2007, Pages 620-626

  Mandal, S ^a   Venkatesh, Pradeep ^a   Sampangi, R ^a   Garg, S ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Bevacizumab; Myopic choroidal neovascularization; Optical coherence tomography

Indexed keywords

BEVACIZUMAB; GATIFLOXACIN; POVIDONE IODINE;

ADULT; AGED; ARTICLE; CATARACT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IRIDOCYCLITIS; MALE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; REFRACTION ERROR; RETINA; RETINA DETACHMENT; RETINA EDEMA; RETINA TEAR; STATISTICAL SIGNIFICANCE; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; THICKNESS; THROMBOEMBOLISM; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 35348944795     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210701700422     Document Type: Article

References (20)

1. Secretan M, Kuhn D, Soubrane G, Coscas G. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 1997; 7: 307-16.
2. Johnson DA, Yannuzzi LA, Shakin JL, Lightman DA. Lacquer cracks following laser treatment of choroidal neovascularization in pathologic myopia. Retina 1998; 18: 118-24.
3. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 2001; 108: 841-52.
4. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia. 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 2003; 110: 667-73.
5. Krebs I, Binder S, Stolba U, Glittenberg C, Brannath W, Goll A. Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy. Am J Ophthalmol 2005; 140: 416-25.
6. Ruiz-Moreno JM, de la Vega C. Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br J Ophthalmol 2001; 85: 1041-3.
7. Avila MP, Weiter JJ, Jalkh AE, et al. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984; 91: 1573-81.
8. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983; 90: 923-6.
9. Hotchkiss ML, Fine SL. Pathologic myopia and choroidal neovascularization. Am J Ophthalmol 1981; 91: 177-83.
10. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization. A 10-year follow-up. Ophthalmology 2003; 110: 1297-305.
11. Degenring RF, Jonas JB. Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularization [letter]. Acta Ophthalmol Scand 2005; 83: 621.
12. Potter MJ, Szabo SM, Ho T Combined photodynamic therapy and intravitreal triamcinolone for the treatment of myopic choroidal neovascularization in a 13-year old girl. Graefes Arch Clin Exp Ophthalmol 2005; 21: 1-3.
13. Hamelin N, Glacet-Bernard A, Brindeau C, et al. Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs. surgical removal. Am J Ophthalmol 2002; 133: 530-6.
14. Bottoni F, Perego E, Airaghi P, et al. Surgical removal of subfoveal choroidal neovascular membranes in high myopia. Graefes Arch Clin Exp Ophthalmol 1999; 237: 573-82.
15. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035-47.
16. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72.
17. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142: 1-9.
18. Nguyen QD, Shah S, Tatlipinar S, et al. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005; 89: 1368-70.
19. Yamamoto I, Rogers AH, Reichel E, Yates P, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br J Ophthalmol 2007; 91: 157-60.
20. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularization caused by pathological myopia. Br J Ophthalmol 2007; 91: 161-5.